Browse by author
Lookup NU author(s): Pauline Heslop,
Professor Caroline AustinORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Type II topoisomerases are required for the management of DNA superhelicity and chromosome segregation, and serve as frontline targets for a variety of small-molecule therapeutics. To better understand how these enzymes act in both contexts, we determined the 2.9-angstrom-resolution structure of the DNA cleavage core of human topoisomerase II alpha (TOP2A) bound to a doubly nicked, 30-bp duplex oligonucleotide. In accord with prior biochemical and structural studies, TOP2A significantly bends its DNA substrate using a bipartite, nucleolytic center formed at an N-terminal dimerization interface of the cleavage core. However, the protein also adopts a global conformation in which the second of its two inter-protomer contact points, one at the C-terminus, has separated. This finding, together with comparative structural analyses, reveals that the principal site of DNA engagement undergoes highly quantized conformational transitions between distinct binding, cleavage, and drug-inhibited states that correlate with the control of subunit-subunit interactions. Additional consideration of our TOP2A model in light of an etoposide-inhibited complex of human topoisomerase II beta (TOP2B) suggests possible modification points for developing paralog-specific inhibitors to overcome the tendency of topoisomerase II-targeting chemotherapeutics to generate secondary malignancies. (C) 2012 Elsevier Ltd. All rights reserved.
Author(s): Wendorff TJ, Schmidt BH, Heslop P, Austin CA, Berger JM
Publication type: Article
Publication status: Published
Journal: Journal of Molecular Biology
Print publication date: 07/12/2012
ISSN (print): 0022-2836
Publisher: Academic Press
Altmetrics provided by Altmetric